STOCK TITAN

Harrow Health Inc - HROW STOCK NEWS

Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.

Harrow Health Inc (HROW) is a leading developer of ophthalmic pharmaceuticals and non-intravenous sedation therapies, addressing critical needs in eyecare and procedural medicine. This dedicated news hub provides investors and healthcare professionals with timely access to official announcements and objective updates about the company's progress.

Our curated collection features earnings reports, regulatory milestones, and product development updates, offering a comprehensive view of HROW's strategic direction. Users will find essential information on FDA approvals, clinical trial results, and partnership announcements that shape the company's position in the pharmaceutical sector.

Key content categories include financial disclosures, research breakthroughs, and manufacturing updates related to compounded medications and sedation therapeutics. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.

Bookmark this page for streamlined access to HROW's latest developments. Check back regularly for authoritative updates on innovations in ocular surface disease treatments and non-IV sedation solutions that demonstrate the company's commitment to advancing patient care.

Rhea-AI Summary

Harrow Health (NASDAQ: HROW), an ophthalmic-focused healthcare company, has launched a redesigned corporate and investor website aimed at enhancing user experience and accessibility of historical and current information. The site showcases Harrow's journey as a leading eye health provider, featuring its mission, product pipeline, and commitment to accessible eyecare. Key assets include ImprimisRx and Visionology, along with equity stakes in several pharmaceutical companies. The site also includes Letters to Stockholders and a Corporate Presentation to facilitate investor engagement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) announced a multi-center retrospective study demonstrating significant improvements in patients with dry eye disease using its Klarity-C Drops® (cyclosporine 0.1%). Published in Clinical Ophthalmology, the study involved 50 patients and showed a marked decrease in ocular surface disease index (OSDI) scores and corneal staining grades after three months of treatment. The study highlighted no adverse events and emphasized Klarity-C's advantages over existing treatments, including its affordability and lack of insurance hurdles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
none
-
Rhea-AI Summary

Harrow Health reported record first-quarter 2021 results, achieving revenues of $15.4 million, up 31% from $11.8 million year-over-year. Adjusted EBITDA reached $4.3 million, significantly higher than the previous year's $0.4 million. Segment contribution from ImprimisRx rose to $5.7 million, while DEXYCU® sales commissions increased 39% over Q4 2020, totaling $485,000. GAAP operating income improved to $2.9 million from an operating loss of $0.6 million, and gross margins increased to 75.6%, compared to 69% last year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.41%
Tags
Rhea-AI Summary

Harrow Health (NASDAQ: HROW) announced the completion of a private sale of 440,000 shares of Series B Cumulative Preferred Stock, raising approximately $10.67 million. The funds will support general corporate purposes, including strategic product acquisitions and working capital. CEO Mark L. Baum highlighted that this transaction, along with previous fund raises totaling over $75 million in 2021, strengthens the company’s financial position for pursuing FDA-approved ophthalmic drug candidates. Harrow's focus remains on growth in the ophthalmic healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.16%
Tags
none
-
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) announced the closing of an additional $5 million in 8.625% senior notes due 2026, following the exercise of the underwriters’ option from a previous $50 million offering. The total gross proceeds from this issuance amount to $55 million before fees. The additional notes will trade under the symbol HROWL. Funds will be allocated for general corporate purposes, including product acquisitions and capital expenditures. Both the notes and additional notes received a 'BB' rating from Egan-Jones Ratings Company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.16%
Tags
none
-
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) will announce its Q1 2021 financial results on May 11, 2021, after market close. The company specializes in ophthalmology and will provide a business update during a conference call at 4:45 p.m. ET on the same day. Investors can access the call details and results on the company’s website. Harrow Health owns ImprimisRx and Visionology, and holds substantial equity in Eton Pharmaceuticals and others. For more details, visit harrowinc.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
Rhea-AI Summary

Harrow Health (NASDAQ: HROW) has successfully closed a public offering of $50 million in senior notes, yielding approximately $48 million in net proceeds. The 8.625% senior notes, due in 2026, are set to trade on Nasdaq under the symbol 'HROWL'. Funds will primarily be used to repay $15.5 million of existing debt, with remaining proceeds allocated for general corporate purposes, including strategic acquisitions and working capital. The offering was rated 'BB' by Egan-Jones Ratings Company, enhancing investor confidence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary

Harrow Health, an ophthalmic healthcare company, announced a public offering of $50 million in senior notes with an interest rate of 8.625%, due in 2026. The offering is expected to close on April 20, 2021, with a potential additional $5 million from underwriters. Proceeds will be used to repay $15.5 million in existing borrowings and fund general corporate purposes, including strategic acquisitions. The notes, rated 'BB,' will be listed on Nasdaq under the symbol 'HROWL.' The offering follows the company's SEC-approved shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.59%
Tags
-
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) has launched a public offering of $25 million in senior notes due 2026, pending market conditions. The notes received a "BB" rating from Egan-Jones Ratings Company. Proceeds are intended to repay $15.5 million of outstanding borrowings under a term loan and for general corporate purposes including strategic acquisitions and working capital. The offering is made under an effective SEC registration statement. B. Riley Securities and others are managing the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.31%
Tags
none
Rhea-AI Summary

Harrow Health, Inc. (NASDAQ: HROW) reported preliminary unaudited financial results for Q1 2021, estimating total revenue between $14.9 million and $15.5 million with an Adjusted EBITDA exceeding $2.7 million. As of March 31, 2021, the company had approximately $6.5 million in cash and cash equivalents, which increased by $10.6 million from the sale of shares in Eton Pharmaceuticals. The final results will be announced on May 11, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.31%
Tags
Harrow Health Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

855.34M
30.01M
13.49%
59.11%
7.72%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE